Read by QxMD icon Read

Radioiodine therapy

Jochen Hammes, Lutz van Heek, Melanie Hohberg, Manuel Reifegerst, Simone Stockter, Markus Dietlein, Markus Wild, Alexander Drzezga, Matthias Schmidt, Carsten Kobe
PURPOSE: Radioiodine has been used for the treatment of benign thyroid diseases for over 70 years. However, internationally, there is no common standard for pretherapeutic dosimetry to optimally define the individual therapy activity. Here, we analyze how absorbed tissue doses are influenced by different approaches to pretherapeutic activity calculation of varying complexity. METHODS: Pretherapeutic determination of treatment activity was retrospectively recalculated in 666 patients who had undergone radioiodine therapy for benign thyroid diseases (Graves' disease, non-toxic goiter, and uni- and multinodular goiter)...
December 12, 2018: EJNMMI Physics
Xiaodong Xu, Lujie Yuan, Yongkang Gai, Qingyao Liu, Lianglan Yin, Yaqun Jiang, Yichun Wang, Yongxue Zhang, Xiaoli Lan
PURPOSE: There has been no satisfactory treatment for advanced melanoma until now. Targeted radionuclide therapy (TRNT) may be a promising option for this heretofore lethal disease. Our goal in this study was to synthesize 131 I-N-(2-(diethylamino)ethyl)-5-(iodo-131I)picolinamide (131 I-5-IPN) and evaluate its therapeutic ability and toxicity as a radioiodinated melanin-targeting therapeutic agent. METHODS: The trimethylstannyl precursor was synthesized and labeled with 131 I to obtain 131 I-5-IPN...
December 11, 2018: Journal of Experimental & Clinical Cancer Research: CR
Laurent Navarro, Marion Berdal, Michel Chérel, Frédéric Pecorari, Jean-François Gestin, François Guérard
125 I- and 211 At-labeled azide and tetrazine based prosthetic groups for bioorthogonal conjugation were designed and tested in a comparative study of five bioorthogonal systems. All five bioconjugation reactions conducted on a model clickable peptide led to quantitative yields within less than a minute to several hours depending on the system used. Transferability to the labeling of an IgG was demonstrated with one of the bioorthogonal system. This study provides several new alternatives to the conventional and suboptimal approach currently in use for radioiodination and astatination of biomolecules and should accelerate the development of new probes with these radionuclides for applications in nuclear imaging and targeted alpha-therapy...
November 26, 2018: Bioorganic & Medicinal Chemistry
Nadia Sawicka-Gutaj, Paulina Ziółkowska, Jerzy Sowiński, Agata Czarnywojtek, Katarzyna Milczarczyk, Paweł Gut, Marek Ruchała
INTRODUCTION Goiter recurrence occurs in a substantial number of patients after thyroid resection. OBJECTIVES We aimed to investigate the prevalence and risk factors of recurrent goiters, influence of goiter recurrence on patient quality of life (QoL) and the efficacy of therapy with radioactive iodine (RAI). PATIENTS AND METHODS This was a case-control study. All thyroidectomized patients admitted within the past year to the outpatient department were included in the study and their medical records were analyzed...
December 5, 2018: Polish Archives of Internal Medicine
Mehdi Dehghani, Saranaz Jangjoo, Ahmad Monabati, Dena Masoomi Bandari, Nasrin Namdari
The standard therapy for thyroid cancer is total or near total thyroidectomy, followed by the administration of radioactive iodine for remnant ablation or residual disease. Patients with radioiodine therapy are predisposed to second malignant neoplasms in organs such as central nervous system (CNS), breast, prostate, kidney, bone marrow, salivary gland, and digestive tract. Exposure to carcinogen including occupational and therapy related hazard, aging and genetic susceptibility are other causes of second primary cancers...
November 2018: Iranian Journal of Medical Sciences
Ka Kit Wong, Barry L Shulkin, Milton D Gross, Anca M Avram
Objective: To evaluate the success rate of therapeutic administration of a single calculated 131 I activity for eliminating hyperthyroidism due to Graves' disease. Methods and materials: Patients with Graves' hyperthyroidism underwent pinhole thyroid imaging, 24-h radioactive iodine uptake (RAIU) measurements and clinical examination and received a calculated 131 I activity of 0.2 mCi per estimated gram of thyroid tissue, adjusted for the 24-h RAIU. The goal of RAI treatment was to achieve hypothyroidism within 3-6 months of 131 I administration...
2018: Clinical Diabetes and Endocrinology
Tharsana Selvakumar, Marloes Nies, Mariëlle S Klein Hesselink, Adrienne H Brouwers, Anouk N A van der Horst-Schrivers, Esther N Klein Hesselink, Wim J E Tissing, Arjan Vissink, Thera P Links
Pediatric differentiated thyroid cancer (DTC) is a rare disease. Initial treatment of DTC consists of a (near) total thyroidectomy and radioactive iodine (131 I) therapy. Previous studies in adults showed that 131 I treatment may result in a reduced salivary gland function. Studies regarding salivary gland function in children treated for DTC are sparse. Our aim was to assess long-term effects of 131 I treatment on salivary gland function in survivors of pediatric DTC. Methods: In a nationwide cross-sectional study, salivary gland function of patients treated for pediatric DTC between 1970 and 2013 (>5 years after diagnosis, ≥18 years old at time of evaluation) was studied...
November 30, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Jonathan C P Roos, Carla Moran, V Krishna Chatterjee, Joanne Jones, Alasdair Coles, Rachna Murthy
Alemtuzumab-a monoclonal antibody targeting the CD52 glycoprotein expressed by most mature leucocytes-effectively decreases relapse rate and disability progression in early, relapsing-remitting multiple sclerosis (MS). However, secondary autoimmune disorders complicate therapy in nearly 50% of treated patients, with Graves' disease being the most common. Rarely, thyroid eye disease (TED) ensues; only seven such cases have been reported. Our aim was to analyse the largest series of MS patients developing thyroid eye disease after alemtuzumab treatment...
November 29, 2018: Eye
Selvihan Beysel, Nilnur Eyerci, Ferda Alparslan Pinarli, Mahmut Apaydin, Muhammed Kizilgul, Mustafa Caliskan, Ozgur Ozcelik, Seyfullah Kan, Erman Cakal
This is the first study to investigate the effect of vitamin D receptor ( VDR) gene single-nucleotide polymorphisms on the clinicopathologic features of papillary thyroid cancer in Turkey. A total of 165 patients with papillary thyroid cancer and 172 controls were included in this case-control study. VDR gene single-nucleotide polymorphisms FokI (rs2228570), BsmI (rs1544410), ApaI (rs7975232), and TaqI (rs731236) were evaluated using reverse-transcription polymerase chain reaction. VDR gene polymorphisms BsmI, ApaI, and TaqI did not differ between the papillary thyroid cancer group and control group (p > 0...
November 2018: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
D Vejrazkova, J Vcelak, E Vaclavikova, M Vankova, K Zajickova, M Duskova, J Vrbikova, B Bendlova
Graves' disease affects approximately 3 % of women and 0.5 % of men. The first-choice therapy is based on the administration of thyrostatic drugs. However, approximately half of patients relapse within two years of discontinuation. These patients must then decide whether to re-initiate thyrostatics, which may have serious side effects, or to undergo surgery or radioiodine treatment. Familial forms of Graves' disease indicate a significant genetic component, with twin studies demonstrating a contribution of genetic factors up to 70-80 %...
November 28, 2018: Physiological Research
Markus Luster, Cumali Aktolun, Isabel Amendoeira, Marcin Barczyński, Keith C Bible, Leonidas H Duntas, Rossella Elisei, Daria Handkiewicz-Junak, Martha Hoffmann, Barbara Jarzab, Laurence Leenhardt, Thomas J Musholt, Kate Newbold, Iain James Nixon, Jan Smit, Manuel Sobrinho-Simões, Julie Ann Sosa, R Michael Tuttle, Frederik Verburg, Leonard Wartofsky, Dagmar Führer-Sakel
BACKGROUND: The American Thyroid Association (ATA) Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer (DTC) are highly influential practice recommendations. The latest revision appeared in 2015 ("ATA 2015"). These guidelines were developed predominantly by North American experts. European experts frequently have different perspectives, given epidemiological, technological/methodological, practice organization, and medicolegal differences between the respective regions...
November 28, 2018: Thyroid: Official Journal of the American Thyroid Association
Margret Ehlers, Matthias Schott, Stephanie Allelein
Graves' disease (GD) is the most common cause for hyperthyroidism in iodine-replete areas. The disease is caused by the appearance of stimulating TSH receptor autoantibodies (TRAb) leading to hyperthyroidism. Blocking and neutral TRAb have, however, also been described. TRAb can be measured either by competition assays, assays using a bridge technology or bioassays (for discriminating stimulating vs. blocking antibodies). Therapy of GD with antithyroid drugs belonging to the group of thionamides is the first-line treatment to be continued for 12 up to 18 months...
January 1, 2019: Frontiers in Bioscience (Landmark Edition)
Oussama ElMokh, Vincent Taelmann, Piotr Radojewski, Matthias Andreas Roelli, Amandine Stooss, Rebecca A Dumont, Matthias Dettmer, Wayne Phillips, Martin Alexander Walter, Roch-Philippe Régis Charles
Anaplastic thyroid carcinoma (ATC) is refractory to radioiodine therapy in part due to impaired iodine metabolism. We targeted the MAPK and PI3'K pathways with the intent to induce radioiodine uptake for radioiodine treatment of ATC. Methods: Human ATC cells were used to evaluate the ability of pharmacological inhibition of the mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways to induce radioiodine uptake. Thyrocyte-specific double mutant BRAFV600E PIK3CAH1047R mice were treated with a MEK inhibitor followed by radioiodine treatment and tumor burden was monitored by ultrasound imaging...
November 21, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Takashi Fujii, Satoru Takeuchi, Terushige Toyooka, Naoki Otani, Kojiro Wada, Kentaro Mori
Papillary thyroid carcinoma is the most common thyroid malignancy and usually has an indolent clinical course with a good prognosis. Brain metastasis from thyroid cancer is very rare, occurring in only 0.8-1.3% of all papillary thyroid carcinomas; therefore, the prognosis and treatment of the metastatic tumor are unclear. We describe 5 cases of brain metastases from papillary thyroid carcinoma treated with surgery between 2013 and 2017. Intracranial tumor resection was performed and brain metastases were pathologically diagnosed as papillary thyroid carcinoma in 2 men and 3 women aged 62-72 years(mean 67 years)...
November 2018: No Shinkei Geka. Neurological Surgery
Nurcan Edis, Muge Oner Tamam
The aim of this study is to evaluate the radiation safety of caregiving people contacting the child and adolescent patients with thyroid cancer who received radioactive iodine-131 (RIT) treatment by comparison with external dose rate measurements of adult patients according to their administered activities and days of hospitalization. We retrospectively evaluated external dose rate measurement of 158 children and adolescent patients and 158 adult patients. During the RIT, the hospitalization time were grouped as 2, 3 and 4 d, and the administered activities as <3700, 3700 and >3700 MBq...
November 17, 2018: Radiation Protection Dosimetry
Ivan Blažeković, Tomislav Jukić, Roko Granić, Marija Punda, Maja Franceschi
Papillary thyroid carcinoma (PTC) is considered one of the most favorable tumors, indolent, with rare distant dissemination. Lungs and bones are the most common metastatic sites. Unusual sites of PTC distant metastases are extremely rare. Brain, liver, skin, kidney, pancreas, and adrenal gland PTC metastases have been sporadically reported in the literature. An 86-year-old female patient underwent total thyroidectomy and neck dissection due to PTC. Postoperative whole body iodine-131 scintigraphy with I-131 SPECT/CT of the abdomen revealed radioiodne avid left adrenal gland metastasis together with high postoperative serum thyroglobulin (Tg) value of more than 5000 µg/L and high serum Tg antibodies...
June 2018: Acta Clinica Croatica
Zhengyuan Zhou, Darryl McDougald, Nick Devoogdt, Michael R Zalutsky, Ganesan Vaidyanathan
ImmunoPET agents are being investigated to assess the status of epidermal growth factor receptor 2 (HER2) in breast cancer patients with the goal of selecting those likely to benefit from HER2-targeted therapies and monitoring their progress after these treatments. We have been exploring the use of single domain antibody fragments (sdAbs) labeled with 18 F using residualizing prosthetic agents for this purpose. In this study, we have labeled two sdAbs that bind to different domains on the HER2 receptor, 2Rs15d and 5F7, using 2,3,5,6-tetrafluorophenyl 6-[18 F]fluoronicotinate ([18 F]TFPFN) and evaluated their HER2 targeting properties in vitro and in vivo...
November 28, 2018: Molecular Pharmaceutics
Ai Yoshihara, Kenji Iwaku, Jaeduk Yoshimura Noh, Natsuko Watanabe, Yo Kunii, Hidemi Ohye, Miho Suzuki, Masako Matsumoto, Nami Suzuki, Rie Tadokoro, Chihiro Sekiyama, Marino Hiruma, Kiminori Sugino, Koichi Ito
The serum TSH receptor antibody (TRAb) titers of Graves' disease (GD) patients is known to increase after radioiodine (RAI) therapy and remain high for years. The incidence of neonatal hyperthyroidism (NH) among the newborns born to mothers with GD who conceived after RAI therapy have not been reported in the past. Objective; To investigate the incidence of NH among the newborns born to mothers who conceived within 2 years after RAI therapy, and to identify predictors of NH. Patients; The cases of 145 GD patients who conceived within 2 years after RAI therapy were retrospectively reviewed, and information regarding their newborns was collected...
November 14, 2018: Thyroid: Official Journal of the American Thyroid Association
Filippo De Luca, Mariella Valenzise
Graves' disease (GD) is a disorder, in which auto-immunity against the thyroid- stimulating hormone (TSH) receptor is the pivotal pathogenetic element. This disease may have different clinical manifestations, the most common being thyrotoxicosis. Treatment of this condition differs according to its etiology, but there is currently no evidence-based therapeutic strategy which is universally adopted in all countries. Areas covered: a systematic review of the updates on the management of pediatric GD was performed using the Pubmed data base until March 2018...
November 2018: Expert Review of Clinical Pharmacology
Steve Swenson, Radu O Minea, Cao Duc Tuan, Thu-Zan Thein, Thomas C Chen, Francis S Markland
We developed a bacterial expression system to produce a recombinant disintegrin, vicrostatin (VCN), whose structure is based on a natural disintegrin isolated from southern copperhead snake venom. Our goal is to develop VCN for potential clinical translation as an anti-cancer agent. VCN is a peptide of 69 amino acids with a single tyrosine residue. We have employed VCN as integrin-targeted radionuclide therapy (brachytherapy) for treatment of glioblastoma (GBM, glioma). GBM is a deadly brain cancer that doesn't discriminate between sexes and knows no age limit...
November 8, 2018: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"